SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Lexicon Pharmaceuticals, Inc. – ‘10-Q’ for 3/31/19 – ‘EX-10.2’

On:  Wednesday, 5/1/19, at 4:13pm ET   ·   For:  3/31/19   ·   Accession #:  1062822-19-17   ·   File #:  0-30111

Previous ‘10-Q’:  ‘10-Q’ on 11/1/18 for 9/30/18   ·   Next:  ‘10-Q’ on 8/1/19 for 6/30/19   ·   Latest:  ‘10-Q’ on 5/2/24 for 3/31/24   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 5/01/19  Lexicon Pharmaceuticals, Inc.     10-Q        3/31/19   51:3.7M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    361K 
 2: EX-10.1     Material Contract                                   HTML     17K 
 3: EX-10.2     Material Contract                                   HTML     29K 
 4: EX-10.3     Material Contract                                   HTML     22K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     24K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
14: R1          Document and Entity Information Document            HTML     41K 
15: R2          Consolidated Balance Sheets (Unaudited)             HTML    109K 
16: R3          Balance Sheet Parenthetical (Parenthetical)         HTML     43K 
17: R4          Consolidated Statements of Comprehensive Loss       HTML     62K 
                (Unaudited)                                                      
18: R5          Statements of Comprehensive Loss Parenthetical      HTML     18K 
                (Parenthetical)                                                  
19: R6          Consolidated Statements of Stockholders' Equity     HTML     52K 
                (Unaudited)                                                      
20: R7          Consolidated Statements of Cash Flows (Unaudited)   HTML     87K 
21: R8          Summary of Significant Accounting Policies (Notes)  HTML    106K 
22: R9          Recent Accounting Pronouncements Level 1 (Notes)    HTML     21K 
23: R10         Cash and Cash Equivalents and Investments           HTML     71K 
24: R11         Fair Value Measurements                             HTML     56K 
25: R12         Debt Obligations                                    HTML     33K 
26: R13         Commitments and Contingencies                       HTML     32K 
27: R14         Collaboration and License Agreements                HTML     50K 
28: R15         Subsequent Event (Notes)                            HTML     20K 
29: R16         Summary of Significant Accounting Policies          HTML    106K 
                (Policies)                                                       
30: R17         Summary of Significant Accounting Policies          HTML     29K 
                (Tables)                                                         
31: R18         Summary of Significant Accounting Policies Equity   HTML     66K 
                Incentive Awards (Tables)                                        
32: R19         Cash and Cash Equivalents and Investments (Tables)  HTML     68K 
33: R20         Fair Value Measurements (Tables)                    HTML     52K 
34: R21         Summary of Significant Accounting Policies          HTML     25K 
                Inventory (Details)                                              
35: R22         Summary of Significant Accounting Policies Other    HTML     19K 
                Intangible Assets (Details)                                      
36: R23         Summary of Significant Accounting Policies          HTML     19K 
                Impairment of Long-lived Assets (Details)                        
37: R24         Summary of Significant Accounting Policies          HTML     19K 
                Goodwill (Details)                                               
38: R25         Summary of Significant Accounting Policies          HTML     36K 
                Stock-based Compensation Valuation (Details)                     
39: R26         Summary of Significant Accounting Policies          HTML     68K 
                Stock-based Compensation Summary (Details 1)                     
40: R27         Recent Accounting Pronouncements (Details)          HTML     18K 
41: R28         Cash and Cash Equivalents and Investments (Details  HTML     38K 
                1)                                                               
42: R29         Cash and Cash Equivalents and Investments (Details  HTML     18K 
                2)                                                               
43: R30         Fair Value Measurements (Details 1)                 HTML     31K 
44: R31         Debt Obligations (Details)                          HTML     59K 
45: R32         Commitments and Contingencies (Details)             HTML     24K 
46: R33         Commitments and Contingencies Details 2 (Details)   HTML     37K 
47: R34         Collaboration and License Agreements (Details)      HTML     67K 
48: R35         Subsequent Event (Details)                          HTML     20K 
50: XML         IDEA XML File -- Filing Summary                      XML     82K 
49: EXCEL       IDEA Workbook of Financial Reports                  XLSX     53K 
 8: EX-101.INS  XBRL Instance -- lxrx-20190331                       XML    876K 
10: EX-101.CAL  XBRL Calculations -- lxrx-20190331_cal               XML    116K 
11: EX-101.DEF  XBRL Definitions -- lxrx-20190331_def                XML    432K 
12: EX-101.LAB  XBRL Labels -- lxrx-20190331_lab                     XML    943K 
13: EX-101.PRE  XBRL Presentations -- lxrx-20190331_pre              XML    533K 
 9: EX-101.SCH  XBRL Schema -- lxrx-20190331                         XSD    107K 
51: ZIP         XBRL Zipped Folder -- 0001062822-19-000017-xbrl      Zip    133K 


‘EX-10.2’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  
Exhibit 10.2

NOTICE OF STOCK OPTION GRANT

(Non-Employee Director Stock Option)

To carry out the purposes of the Lexicon Pharmaceuticals, Inc. 2017 Non-Employee Directors’ Equity Incentive Plan (the “Plan”), by providing ______________ (“Director”) the opportunity to purchase shares of Common Stock, par value $0.001 per share (“Stock”), of LEXICON PHARMACEUTICALS, INC. (the “Company”) in accordance with the Plan, the Company hereby provides notice to Director as follows:

1.    Grant of Option. Effective as of ______________ (the “Grant Date”), the Company has granted Director the right and option (the “Option”) to purchase all or any part of an aggregate of ________ shares of Stock, on the terms and conditions set forth in this Notice and in the Plan. The Option shall be treated as a non-statutory stock option and not as an “incentive stock option” within the meaning of section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”).

1.    Exercise Price. The price at which Director may purchase Stock upon exercise of the Option (the “Exercise Price”) shall be $______ per share, which has been determined to be the Fair Market Value (as defined in the Plan) of the Stock on the Grant Date. The Exercise Price is subject to adjustment under certain circumstances as provided in the Plan.

2.    Term. The Option shall expire on the 10th anniversary of the Grant Date, subject to earlier termination under the circumstances specified in Section 8 of this Notice.

3.    Exercisability and Vesting. Subject to the terms and conditions set forth in this Notice and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time during the term of the Option, to purchase the number of shares of Stock that have vested and become exercisable in accordance with this Notice. The Option shall vest and become exercisable with respect to [1/12 of the total number of shares of Stock subject to the Option each month after grant for 12 months after the Grant Date] [one third of the total number of shares of Stock subject to the Option on each of the first three anniversaries of the Grant Date]; provided that, such vesting schedule may be accelerated upon a change in control of the Company pursuant to the provisions of the Plan and; provided further, that, upon the termination of Director’s Continuous Service (as defined in the Plan), the Option shall cease to vest and shall terminate with respect to all shares of Stock that have not vested and become exercisable prior to such time.

4.    Procedures for Exercise. Subject to the terms and conditions set forth in this Notice and the Plan, the Option may be exercised by delivery to the Company at its principal executive office of (i) written notice addressed to the Secretary of the Company specifying the number of shares of Stock as to which the Option is being exercised and (ii) payment in full of the Exercise Price for such shares. The Exercise Price shall be paid in cash or in such other manner as may be authorized by the administrator of the Plan in accordance with the terms of the Plan. If the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have not been registered under the Securities Act of 1933 (the “Securities Act”), the Company may require Director, as a condition to Director’s exercise of the Option, to enter into a stock purchase agreement containing such representations and warranties as the Company may deem necessary to permit the issuance of the Stock purchased upon exercise of the Option in compliance with the Securities Act and applicable state securities laws.

5.    No Rights of Ownership in Stock Before Issuance. No person shall be entitled to the rights and privileges of stock ownership with respect to any shares of Stock issuable upon exercise of the Option until such shares have been issued in accordance with the terms of this Notice and the Plan.

6.    Non-Transferability. The Option may not be transferred by Director otherwise than (i) by will or the laws of descent and distribution, by instrument to an inter vivos or testamentary trust or by gift to a member of Director’s immediate family, in each case in accordance with the terms of the Plan, or (ii) pursuant to a qualified domestic relations order (as defined in Title I of the Employee Retirement Income Security Act of 1974, as amended, or the rules thereunder).

7.    Termination of Option. If Director’s Continuous Service is terminated for any reason other than the Disability (as defined in the Plan) or death of Director, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of such termination, for a period of six months after the date of such termination (subject to extension as provided in the Plan, but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which six-month period this Notice and Director’s right to exercise the Option shall terminate. If Director’s Continuous Service is terminated because of Disability of Director, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of such termination, for a period of 12 months after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which 12-month period this Notice and Director’s right to exercise the Option shall terminate. If (i) Director’s Continuous Service is terminated because of death of Director or (ii) Director dies within the three-month period after the termination of Director’s Continuous Service for a reason other than death, the Option shall remain exercisable, with respect to the shares of Stock that had vested under the terms of this Notice before the date of death, for a period of 18 months after the date of such termination (but in no event later than the expiration date of the Option specified in Section 3 of this Notice), following which 18-month period this Notice and the right to exercise the Option shall terminate. Notwithstanding the foregoing, if the Director is removed from the Company’s Board of Directors for cause in accordance with the Company’s Bylaws, this Notice and Director’s right to exercise any portion of the Option, whether or not vested, shall terminate at the commencement of business on the date of such removal.

8.    Withholding of Tax. To the extent that the Company is required under applicable federal or state income tax laws to withhold any amount on account of any present or future tax imposed as a result of the exercise of the Option, Director shall pay the Company, at the time of such exercise, funds in an amount sufficient to permit the Company to satisfy such withholding obligations in full. If Director fails to pay such amount, the Company shall be authorized (i) to withhold from any cash remuneration then or thereafter payable to Director any tax required to be withheld or (ii) to refuse to issue or transfer any shares otherwise required to be issued pursuant to the terms of this Notice.

9.    Status of Stock. (a) Unless the offering, sale and delivery of the shares of Stock issuable upon exercise of the Option have been registered under the Securities Act, Director agrees that any shares of Stock purchased upon exercise of the Option shall be acquired for investment without a view to distribution, within the meaning of the Securities Act, and shall not be sold, transferred, assigned, pledged or hypothecated in the absence of an effective registration statement under the Securities Act and applicable state securities laws or an applicable exemption from the registration requirements of the Act and any applicable state securities laws. Director further agrees that the shares of Stock which Director may acquire by exercising the Option will not be sold or disposed of in any manner which would constitute a violation of any other applicable federal or state securities laws. In addition, Director agrees (i) that the certificates representing the shares of Stock issued under this Notice may bear such legend or legends as the administrator of the Plan deems appropriate in order to assure compliance with applicable securities laws, and (ii) that the Company may give instruction to its transfer agent, if any, to stop transfer of the shares of Stock issued under this Notice on the stock transfer records of the Company, if such proposed transfer would, in the opinion of counsel to the Company, constitute a violation of any applicable securities law or any such agreements.

(b)    Director further agrees that the Option granted herein shall be subject to the requirement that if at any time the administrator of the Plan shall determine, in its discretion, that the listing, registration or qualification of the shares of Stock subject to such Option upon any securities exchange or market or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares of Stock hereunder, such Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not reasonably acceptable to the administrator of the Plan.

10.    2017 Non-Employee Directors’ Equity Incentive Plan. The Plan, a copy of which is available for inspection by Director or other persons entitled to exercise this Option at the Company’s principal executive office during business hours, is incorporated by reference in this Notice. The Option is subject to, and the Company and Director agree to be bound by, all of the terms and conditions of the Plan. In the event of a conflict between this Notice and the Plan, the terms of the Plan shall control. Subject to the terms of the Plan, the administrator of the Plan shall have authority to construe the terms of this Notice, and the determinations of the administrator of the Plan shall be final and binding on Director and the Company. This Notice shall constitute a Stock Award Agreement (as defined in the Plan) evidencing the terms and conditions of the Option grant for all purposes under the Plan.



1


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:5/1/198-K
For Period end:3/31/19
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/25/24  Lexicon Pharmaceuticals, Inc.     10-K       12/31/23   68:6.3M
 3/03/23  Lexicon Pharmaceuticals, Inc.     10-K       12/31/22   73:7.6M
 3/10/22  Lexicon Pharmaceuticals, Inc.     10-K       12/31/21   82:7.6M
 3/12/21  Lexicon Pharmaceuticals, Inc.     10-K       12/31/20   82:7.9M
12/11/20  Lexicon Pharmaceuticals, Inc.     424B5                  1:429K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001062822-19-000017   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 12:10:17.2am ET